ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/haematology/myeloid-leukaemias/acute-myeloid-leukaemia
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Myeloid leukaemias / Acute myeloid leukaemia
26
trial(s) found.
NCT07306832
Paed
Phase 1
Recruiting
A Phase 1b Study of the Safety and Pharmacokinetics of Pivekimab Sunirine in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) (
M25-692
)
Acute myeloid leukaemia
WA
6009 - Perth - Perth Children's Hospital
NCT05183035
Paed
Phase 3
Recruiting
A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML (
ITCC-101-APAL2020D
)
Bcl2 inhibitor
anti-CD33 antibody-drug conjugate
antimetabolite
Acute myeloid leukaemia
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT04771130
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies (
BGB-11417-103
)
Bcl2 inhibitor
Acute myeloid leukaemia
Myelodysplastic syndrome
Myelodysplastic/Myeloproliferative disease
NSW
2139 - Concord - Concord Repatriation General Hospital
2217 - Kogarah - St George Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Gold Coast University Hospital
WA
6009 - Nedlands - One Clinical Research
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT04293562
Paed
Phase 3
Recruiting
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations (
AAML1831
)
AXL/FLT3 inhibitor
anti-CD33 antibody-drug conjugate
liposomal cytarabine/daunorubicin
Acute myeloid leukaemia
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
QLD
4101 - South Brisbane - Queensland Children's Hospital (SUSPENDED)
WA
6009 - Perth - Perth Children's Hospital
NCT03409081
Paed
No longer available
Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) (
2215-CL-9200
)
AXL/FLT3 inhibitor
Acute myeloid leukaemia
ACT
2605 - Garran - The Canberra Hospital
ACTRN12626000278336
Haem
Not Applicable
Not yet recruiting
ALLG AMLM28-A3. A randomised study of ambulatory management compared to standard of care for fever related hospitalisation in patients with AML receiving Venetoclax and Azacitidine – a domain of Achieving Durable remissions via Adaptive Pro-survival Targeting in AML (ADAPT) (
ADAPT-ID
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
Acute myeloid leukaemia
ACTRN12626000019303
Haem
Phase 2
Not yet recruiting
A Double-blind, Phase I/II, Randomised Study to Compare the Efficacy of Enzomenib Versus Placebo as Maintenance after Allogeneic Haematopoietic Stem Cell Transplantation in Subjects with Acute Myeloid Leukaemia (AML). (
ACT-MIM-001
)
menin inhibitor
placebo
Acute myeloid leukaemia
Cancer
Myelodysplastic syndrome
ACTRN12625001003460
Haem
Phase 3
Not yet recruiting
ALLG AMLM29
CAVIAT-R
(Combining Anti-BCL2 and intensive chemotherapy in Acute Myeloid Leukaemia (AML) Trial- Randomised) : a multicentre phase III trial for newly diagnosed AML
Amsacrine
Bcl2 inhibitor
Cytarabine
Filgrastim
Fludarabine
Idarubicin
Pegfilgrastim
Posaconazole
Venetoclax
alkylating agent
anthracycline
antimetabolite
azole antifungal
cancer therapy
cancer therapy,Bcl2-targeting
cytotoxic chemotherapy
Acute myeloid leukaemia
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12625000994482
Haem
Phase 1 / Phase 2
Not yet recruiting
ALLG AMLM28/A2 (ADAPT): Achieving Durable remissions via Adaptive Pro-survival Targeting in acute myeloid leukaemia (AML)) – VEN/AZA/Pelcitoclax. A therapeutic arm of the ALLG AMLM28 ADAPT Study-Master Protocol. (
ADAPT-A2
)
Bcl2 inhibitor
Acute myeloid leukaemia
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12625000964415
Haem
Phase 3
Not yet recruiting
ALLG AMLM30/EVOLVE II: Randomised study to assess revumenib in combination with azacitidine + venetoclax in adult patients with newly diagnosed NPM1-mutated or KMT2A-rearranged AML ineligible for intensive chemotherapy (
EVOLVE-II
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
menin-MLL1 inhibitor
Acute myeloid leukaemia
Cancer
ACTRN12625000824460
Haem
Phase 1 / Phase 2
Not yet recruiting
AMLM26/T9 - INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML)): A Multi-arm, Precision-based, Recursive, Platform Trial- PHI-101 (
AMLM26-T9
)
Acute myeloid leukaemia
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12624000738527
Haem
Phase 2
Recruiting
AMLM22/D4: The International AML Platform Consortium (IAPC) trial – is a randomised, 2-arm trial that will investigate the efficacy of oral Azacitidine combined with an allogeneic dendritic cell vaccine vididencel, compared with oral Azacitidine alone, in maintaining or inducing negativity for measurable residual disease (MRD) in AML patients in first complete remission (CR1) following intensive chemotherapy. (
AMLM22-D4-CADENCE
)
DNA methyltransferase inhibitor
antimetabolite
Acute myeloid leukaemia
ACTRN12624000141549
Haem
Phase 1 / Phase 2
Recruiting
AMLM26/T2- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in Acute Myeloid Leukaemia (AML)): A Multi-arm, Precision-based, Recursive, Platform Trial - Ivosidenib + Venetoclax (
AMLM26-T2
)
Bcl2 inhibitor
IDH1 R132 inhibitor
Acute myeloid leukaemia
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12624000082505
Haem
Phase 1 / Phase 2
Recruiting
AMLM26/T1- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre- emptive Therapy in AML): A Multi-arm, Precision- based, Recursive, Platform Trial - Gilteritinib+ Venetoclax (
AMLM26-T1--INTERCEPT
)
AXL/FLT3 inhibitor
Bcl2 inhibitor
Acute myeloid leukaemia
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12624000065594
Haem
Not Applicable
Not yet recruiting
ALLG AMLM28/STOP: Achieving Durable remissions via Adaptive Pro-survival Targeting in Acute Myeloid Leukaemia (AML) (ADAPT): The ADAPT Platform trial - STOP Domain
Azacitidine
Bcl2 inhibitor
DNA methyltransferase inhibitor
Venetoclax
antimetabolite
cancer therapy
cancer therapy,Bcl2-targeting
cancer therapy,DNA methyltransferase-targeting
cytotoxic chemotherapy
Acute myeloid leukaemia
ACTRN12624000006549
Haem
Phase 1 / Phase 2
Recruiting
AMLM26/T3- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in Acute Myeloid Leukaemia (AML)): A Multi-arm, Precision-based, Recursive, Platform Trial - LDAC + Venetoclax (
AMLM26-T3-INTERCEPT
)
Bcl2 inhibitor
Acute myeloid leukaemia
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12623000900617
Haem
Phase 2
Recruiting
AMLM28 Platform Study (Master Protocol) - Achieving Durable remissions via Adaptive Pro-survival Targeting in Acute Myeloid Leukaemia (AML) patients receiving Venetoclax and Azacitidine (VEN-AZA) as frontline therapy (
ALLG
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
Acute myeloid leukaemia
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12622001302741
Haem
Phase 1 / Phase 2
Not yet recruiting
MDS05/D2 - A multicentre phase Ib/II open label randomized platform design study to determine the safety and efficacy of SRA515 and ASTX727 for treatment of intermediate and high risk Myelodysplastic Syndrome (MDS). (
ALLG
)
BRD4 inhibitor
cytidine deaminase inhibitor
Acute myeloid leukaemia
Myelodysplastic syndrome
ACTRN12622001232729
Radonc
Phase 2
Recruiting
A multi-centre phase II, Australian and New Zealand, exploratory study of amendments to conditioning regimens in haplo-identical stem cell transplantation (
The-ANZHIT-2-study
)
Cyclophosphamide
Fludarabine
Mesna
Radiotherapy
Treosulfan
alkylating agent
antimetabolite
cancer therapy
cytotoxic chemotherapy
sodium mercaptoethanesulfonate
Acute lymphoblastic leukaemia
Acute myeloid leukaemia
Chronic myelogenous leukaemia
Myelodysplastic syndrome
Myeloproliferative Neoplasm
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12622000582752
Haem
Phase 1 / Phase 2
Recruiting
AMLM26/T4- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in Acute Myeloid Leukaemia (AML)): A Multi-arm, Precision-based, Recursive, Platform Trial - SNDX5613 (
AMLM26-T4
)
Revumenib
cancer therapy
cancer therapy,KMT2A-targeting
cancer therapy,menin-MLL1-targeting
cancer therapy,menin-targeting
menin-MLL1 inhibitor
menin inhibitor
Acute myeloid leukaemia
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3004 - Melbourne, Southbank - Alfred Health
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12621001265864
Haem
Phase 1 / Phase 2
Recruiting
AMLM26/T5- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in Acute Myeloid Leukaemia (AML)): A Multi-arm, Precision-based, Recursive, Platform Trial - MBG453 OR MBG453 and Azacitidine (
AMLM26-T5
)
DNA methyltransferase inhibitor
anti-TIM3 monoclonal antibody
antimetabolite
Acute myeloid leukaemia
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12621000246886
Paed
Phase 2
Not yet recruiting
AMLM22/D3-The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in subjects with acute myeloid leukaemia in first complete remission. Domain 3 is investigating the safety and efficacy of an Astrazeneca drug labelled AZD5153 as a maintenance therapy option. (
AMLM22-D3
)
BRD4 inhibitor
Acute myeloid leukaemia
ACTRN12613000358741
Haem
Phase 4
Not yet recruiting
The effect of subcutaneous azacitidine on overall survival using the alternate regimen of 75mg/m2/day for 3 days/week (Monday, Wednesday, Friday) for 2 weeks each month in elderly patients (over 65 years old) with high risk myelodysplasia/acute myeloid leukaemia.
DNA methyltransferase inhibitor
antimetabolite
Acute myeloid leukaemia
NSW
2217 - Kogarah - St George Hospital
2500 - Wollongong - Wollongong Hospital
ACTRN12610001031055
Haem
Phase 1 / Phase 2
Recruiting
A Phase Ib/II Clinical Evaluation of the Safety of Combining the mTOR inhibitor Everolimus with 5-Azacitidine in AML
DNA methyltransferase inhibitor
antimetabolite
mTORC1 inhibitor
Acute myeloid leukaemia
ACTRN12610000641099
Haem
Phase 2
Recruiting
A single arm pilot study of azacitidine in myelodysplastic syndrome / acute myeloid leukaemia, with eltrombopag support for thrombocytopenia (
AZA-E
)
DNA methyltransferase inhibitor
antimetabolite
Acute myeloid leukaemia
Myelodysplastic syndrome
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
ACTRN12606000514505
Haem
Phase 3
Not yet recruiting
A Phase III Randomized Study of Cloretazine (VNP40101M) and Cytosine Arabinoside (AraC) in Patients with Acute Myeloid Leukemia in First Relapse to Improve the Overall Remission Rate (
Vion
)
antimetabolite
Acute myeloid leukaemia
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (14)
Not yet recruiting (11)
No longer available (1)
Recruitment Country and State
WA (13)
VIC (13)
NSW (12)
QLD (11)
SA (9)
NZ (5)
ACT (3)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (10)
Phase 2 (6)
Phase 3 (5)
Phase 4 (1)
Trial Type
Haem (19)
Paed (5)
Advanced (1)
Radonc (1)
Cancer Therapy Class
DNA methyltransferase
50%
Bcl2
42%
AXL
12%
FLT3
12%
menin
12%
CD33
8%
KMT2A
8%
menin-MLL1
8%
BRD4
8%
IDH1
4%
IDH1 R132
4%
cytidine deaminase
4%
TIM3
4%
mTOR
4%
mTORC1
4%
Facility
3168 - Clayton - Monash Medical Centre (9)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (9)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (9)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (9)
6150 - Murdoch - Fiona Stanley Hospital (8)
3000 - Melbourne - Peter MacCallum Cancer Centre (8)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (8)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (8)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (8)
4102 - Woolloongabba - Princess Alexandra Hospital (8)
2139 - Concord - Concord Repatriation General Hospital (7)
3004 - Melbourne, Southbank - Alfred Health (7)
4215 - Southport - Gold Coast University Hospital (7)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (7)
2050 - Camperdown - Chris O'Brien Lifehouse (6)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (5)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (4)
6009 - Perth - Perth Children's Hospital (3)
2605 - Garran - The Canberra Hospital (3)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (3)
4101 - South Brisbane - Queensland Children's Hospital (2)
2217 - Kogarah - St George Hospital (2)
3066 - Epping - Northern Hospital (2)
3128 - Box Hill - Box Hill Hospital - Eastern Health (2)
4575 - Birtinya - Sunshine Coast University Hospital (2)
6000 - Perth - Royal Perth Hospital (2)
3052 - Parkville - Royal Children's Hospital Melbourne (1)
NZ.1023 - Grafton - Starship Children's Hospital (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
6009 - Nedlands - One Clinical Research (1)
NZ.0622 - Takapuna - North Shore Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
2031 - Randwick - Sydney Children's Hospital (1)
2145 - Westmead - The Children's Hospital at Westmead (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
2500 - Wollongong - Wollongong Hospital (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
Cancer Type
Acute myeloid leukaemia
Cancer
Haematological malignancy
Leukaemia
Myeloid leukaemia
Myelodysplastic syndrome
Myeloproliferative neoplasm
Myelodysplastic/Myeloproliferative disease
Acute lymphoblastic leukaemia
Chronic leukaemia
Chronic myelogenous leukaemia
Lymphoid leukaemia
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy